# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults

> **NCT03245619** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Pancreatitis, Acute Necrotizing

## Interventions

- **DRUG:** GSK3335065
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03245619
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-22
- **Primary completion:** 2018-05-19
- **Final completion:** 2018-05-19
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The study was terminated as relationship between GSK3335065 and ventricular tachycardia could not be excluded.
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245619, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03245619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*